Matching the standards of clinical trial evidence with application in practice

International Journal of Clinical Practice

Volumn 56, Issue 10, 2002, Pages 772-775

  Sharpe, N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; XAMOTEROL;

CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEART FAILURE; HUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STANDARD;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 0036953366     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Furberg CD. Are drugs within a class interchangeable? Lancet 1999; 354: 1202-1204.
2. Kennedy HL Rosenson RS. Physicians' interpretation of 'class effects'. J Am Coll Cardiol 2002; 40: 19-26.
3. Sharpe N. Clinical trials and the real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther 2002; 16: 75-77.
4. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiological perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
5. Food and Drug Administration. Single-entity barbituates: class labelling guidance. Fed Reg, Dept Health Human Serv 1980; 45: 76356-76367.
6. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358-1361.
7. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
9. Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
10. The Beta-Blocker Evaluation of Survival Trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
11. The Xamoterol in Severe Heart Failure study group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
12. Flather MD, Yusuf S, Kober L, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-1581.
13. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202-2212.
14. Doughty RN, Sharpe V. Optimization of ACE inhibitor therapy in heart failure. Eur Heart J 2002; 23: 1322-1323.
15. Sharpe N. From cardiac to vascular protection: the next chapter. Lancet 1992; 340: 1197-1198.
16. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
17. Furberg CD. Are all angiotensin-converting-enzyme inhibitors interchangeable? J Am Coll Cardiol 2001; 37: 1456-1460.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1996; 344: 1383-1389.
19. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
20. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
21. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
22. Schwartz JS, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRA-CL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
23. Sacks FM. Lipid-lowering therapy in acute coronary syndromes. JAMA 2001; 285: 1758-1760.
24. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998; 352: 1830-1831.
25. Pasternak RC, Smith SC, Bairey-Merz CN et al. ACC/AHA/NHLBI advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028.